Carlos M. Panizo

San Sebastian, PV, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 60 publications

Allogeneic HCT as Consolidation in B-cell Lymphomas After Exposure to Bispecific Antibodies: A GETH-TC Study.

Allogeneic HCT as Consolidation in B-cell Lymphomas After Exposure to Bispecific Antibodies: A GETH-TC Study.

Journal: Blood advances

Published: August 20, 2025

Allogeneic HCT as consolidation in B-cell lymphomas after exposure to bispecific antibodies: a GETH-TC study.

Allogeneic HCT as consolidation in B-cell lymphomas after exposure to bispecific antibodies: a GETH-TC study.

Journal: Blood advances

Published: August 20, 2025

SOX4 in chronic lymphocytic leukaemia: the forgotten transcription factor.

SOX4 in chronic lymphocytic leukaemia: the forgotten transcription factor.

Journal: Blood research

Published: March 27, 2025

Immune dysfunction prior to and during vaccination in multiple myeloma: a case study based on COVID-19.

Immune dysfunction prior to and during vaccination in multiple myeloma: a case study based on COVID-19.

Journal: Blood cancer journal

Published: March 26, 2024

Polatuzumab vedotin plus rituximab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study.

Polatuzumab vedotin plus rituximab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study.

Journal: The Lancet. Haematology

Published: August 22, 2023

Low-risk HPLLs/ABC score patients with splenic marginal zone lymphoma can be safely managed without treatment: Results from a prospective Spanish study.

Low-risk HPLLs/ABC score patients with splenic marginal zone lymphoma can be safely managed without treatment: Results from a prospective Spanish study.

Journal: British journal of haematology

Published: March 07, 2023

Venetoclax improves CD20 immunotherapy in a mouse model of MYC/BCL2 double-expressor diffuse large B-cell lymphoma.

Venetoclax improves CD20 immunotherapy in a mouse model of MYC/BCL2 double-expressor diffuse large B-cell lymphoma.

Journal: Journal for immunotherapy of cancer

Published: February 12, 2023

Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma, including those with poor prognostic factors.

Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma, including those with poor prognostic factors.

Journal: Haematologica

Published: December 05, 2022

Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma.

Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma.

Journal: Blood advances

Published: October 31, 2022

Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma.

Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma.

Journal: Nature medicine

Published: February 02, 2022

Preneoplastic somatic mutations including MYD88L265P in lymphoplasmacytic lymphoma.

Preneoplastic somatic mutations including MYD88L265P in lymphoplasmacytic lymphoma.

Journal: Science advances

Published: January 19, 2022

Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma.

Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma.

Journal: Leukemia & lymphoma

Published: December 06, 2021

Showing 1-12 of 60

Last Updated: 09/26/2026